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Comprehensive histopathological comparison of epidermotropic/dermal metastatic
melanoma and primary nodular melanoma
Aims: Metastatic melanoma involving the epidermis
and/or upper dermis may show significant histologi-
cal overlap with primary cutaneous melanoma, espe-
cially the nodular subtype. Proper histopathological
classification is crucial to appropriate staging and
management, but is often challenging. The aim of
this study was to identify helpful histopathological
features for differentiating epidermotropic/dermal
metastatic melanoma (EDMM) and primary nodular
melanoma (PNM).
Methods and results: A cohort of EDMMs (n = 74)
and PNMs (n = 75) was retrospectively reviewed for
various histopathological features, and the data were
compared between groups by the use of univariate
analysis. Features significantly associated with EDMM
included a tumour size of <2 mm, an absence of
tumour-infiltrating lymphocytes and plasma cells,
monomorphism, and involvement of adnexal epithelium.
Features associated with PNM included a polypoid
(exophytic) configuration, prominent tumour-infiltrating
plasma cells (TIPs), a tumour size of >10 mm, ulcera-
tion, epidermal collarettes, a higher mitotic rate,
necrosis, multiple phenotypes, significant pleomor-
phism, and lichenoid inflammation. In multivariate
analysis, a logistic regression model including large
tumour size, ulceration, prominent TIPs, lichenoid
inflammation and epidermal collarettes was highly
predictive of PNM. Six (8%) EDMMs from three
patients showed an ‘epidermal-only’ or ‘epidermal-
predominant’ pattern closely simulating in-situ or
microinvasive melanoma. Two of these cases were
tested by fluorescence in-situ hybridisation, which
confirmed clonal relationships with their correspond-
ing primary melanomas.
Conclusions: This is the first comprehensive
histopathological comparison of EDMM and PNM.
Recognition of the above histopathological associa-
tions should aid in the correct classification and stag-
ing of cutaneous melanoma. Epidermotropic
metastatic melanomas may occasionally show an epi-
dermal-only/epidermal-predominant pattern; accurate
diagnosis requires prudent clinical correlation and,
when necessary, ancillary molecular tests.
Keywords: epidermotropic, metastatic melanoma, nodular melanoma, staging
Address for correspondence: May P Chan, MD, Department of Pathology, University of Michigan, 1301 Catherine Street, Medical Science I,
M3261, Ann Arbor, MI 48109, USA. e-mail: mpchan@med.umich.edu
© 2017 John Wiley & Sons Ltd.
Histopathology 2018, 72, 472–480. DOI: 10.1111/his.13384
Introduction
Distinguishing between metastatic and primary mela-
nomas is crucial, as the therapy and prognosis differ
widely. Whereas primary melanoma is treated with
wide excision, metastatic melanoma is often treated
with systemic therapy.1 Also, a patient with multiple
primary melanomas is staged on the basis of the
lesion with the worst prognostic parameters, while
patients with satellite and in-transit metastases are
considered to have stage IIIB disease, and those with
distant cutaneous metastases are considered to have
stage IV disease with a 10% 5-year survival rate.2
Because the skin is a common site for melanoma
metastasis, histological differentiation between pri-
mary and metastatic melanomas presents a rather
common diagnostic dilemma. Primary nodular mela-
noma (PNM) typically only minimally involves the
epidermis, frequently raising consideration for meta-
static melanoma even in patients without a prior his-
tory of melanoma, as metastatic melanoma may
develop following complete regression of the primary
tumour.3–5 Conversely, an epidermotropic/dermal
metastatic melanoma (EDMM) may closely mimic a
primary melanoma and be misdiagnosed as such,
particularly when a prior history of melanoma is not
known. Clinical correlation is often imperative in ren-
dering the correct diagnosis. EDMM usually occurs
near the site of a primary melanoma, sometimes pre-
senting in crops.6 In contrast, it is rare for a patient
to present with multiple synchronous primary mela-
nomas.7,8
Historically, epidermal involvement was considered
to be pathognomonic for primary melanoma,9 but
this belief was subsequently disputed.10 Microscopic
features frequently reported in cutaneous metastatic
melanoma included thinning of the epidermis, widen-
ing of the papillary dermis by aggregates of atypical
melanocytes, flanking epidermal collarettes, a lack of
inflammation, monomorphism, and fibrotic
stroma.10,11 Lymphovascular invasion was also
thought to favour EDMM; however, more recent stud-
ies have demonstrated this feature in up to 30% of
primary melanomas.12 Similarly, extension of
intraepidermal melanocytes beyond dermal melano-
cytes (architectural ‘shoulder’) was once considered
to be a unique feature of primary melanoma, but was
later also reported in EDMM.8,13,14 The absence of an
architectural shoulder in PNM further blurs their dis-
tinction.
Further complicating this issue are rare reports of
purely intraepidermal epidermotropic metastatic mel-
anoma.11,14,15 Despite their striking resemblance to
melanoma in situ, the clinical presentation of numer-
ous lesions and their small size, circumscription and
symmetry supported the interpretation of epider-
motropic metastatic melanomas with an ‘epidermal-
only’ pattern.
In this study, we performed a comprehensive
histopathological analysis of EDMM and PNM in
order to identify the most helpful features for differen-
tiating the two.
Materials and methods
This study has been approved by the Institutional
Review Board at the University of Michigan. Our
pathology database was searched for EDMM and
PNM by the use of word searches for ‘nodular’ + ’me-
lanoma’, ‘epidermotropic’ + ’melanoma’, and ‘meta-
static melanoma’ from 2000 to 2016. Final
classification as EDMM or PNM was based on careful
clinicopathological correlation. Patients with prior
history of melanoma were excluded from the PNM
group, whereas patients without a previously diag-
nosed primary melanoma were excluded from the
EDMM group. Metastases distant from the previous
primary melanoma site were also excluded from the
EDMM group; only locoregional metastases (e.g. from
the same extremity) were included. To qualify as
EDMM, a metastatic melanoma should involve the
epidermis/adnexal epithelium and/or the upper der-
mis (papillary dermis or superficial reticular dermis).
Haematoxylin and eosin (H&E)-stained slides of the
final cohort were reviewed by two dermatopatholo-
gists (D.P.A. and M.P.C.) and a pathology resident
(S.L.S.) for various histopathological features, as listed
in Tables 1 and 2. Selected features are defined
below.
A tumour was polypoid (exophytic) if its epicentre
was above the skin surface. An architectural shoulder
was defined as an intraepidermal component extend-
ing at least three rete ridges beyond the dermal com-
ponent. Pleomorphism was scored as follows: 0,
mostly monomorphic cells; 1, pleomorphism appreci-
ated at medium to high magnification; and 2, pleo-
morphism readily appreciated at low magnification,
often with bizarre-looking cells. Tumours consisting
of two or more morphologically distinct cell popula-
tions were considered to have multiple phenotypes.
Mitotic rate was the number of dermal mitotic figures
in a 1-mm2 ‘hot spot’ (i.e. most mitotically active
area). As per the American Joint Committee on Can-
cer guidelines for melanoma,2 tumour-infiltrating
lymphocytes (TILs) were either absent (0), non-brisk
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(1), or brisk (2). Tumour-infiltrating plasma cells
(TIPs) were scored as follows: 0, no intratumoral
plasma cells; 1, rare aggregates of intratumoral
plasma cells only appreciable upon close inspection;
and 2, prominent, readily appreciable aggregates of
intratumoral plasma cells. Regression was defined as
a discrete fibrotic area with melanophages, lympho-
cytes, and increased vascularity. Tumoral melanosis
refers to large aggregates of melanophages replacing
a portion of the melanoma. Unlike lymphovascular
invasion, in which melanoma cells are present within
a vascular lumen, angiotropism refers to extravascu-
lar melanoma cells bulging into the vascular lumen
but covered by endothelial cells.
In univariate analysis (performed by M.P.C.), com-
parison of each feature between EDMM and PNM was
performed with chi-square tests (categorical) or two-
sample t-tests (continuous). Multivariate analysis was
conducted by L.Z. with SAS (version 9.4; SAS Institute,
Cary, NC, USA). A logistic regression model was
obtained by a stepwise variable selection procedure
based on a significance level of 0.15. The parameter
estimates, P-values from Wald chi-square tests and
the area under the receiver operating characteristic
(ROC) curve were reported. A P-value of <0.05 was
considered to be significant.
Fluorescence in-situ hybridisation (FISH) was per-
formed by A.A.A., P.W.H. and M.W. on selected
EDMM cases with an unusual ‘epidermal-only’ or
‘epidermal-predominant’ pattern and their corre-
sponding primary tumours to confirm clonal relation-
ships. Four-micrometre sections were prepared from
each selected formalin-fixed paraffin-embedded tissue
block; one was stained with H&E, and two were
hybridised by use of the Vysis Melanoma FISH probe
kit, including probes 6p25 (RREB1), 6q23 (MYB),
CEP6, and 11q13 (CCND1), and Vysis LSI probes
8q24 (MYC) and 9p21 (CDKN2A)/CEP9, according to
the manufacturer’s instructions. Thirty cells were
evaluated, and the percentage of nuclei with copy
Table 1. Histopathological features showing statistically significant differences between epidermotropic/dermal metastatic





(n = 75) P-value
Specificity
(%)
Greatest diameter <2 mm, no. (%) 19 (26) 0 (0) <0.0001 100
Absence of tumour-infiltrating
plasma cells, no. (%)
67 (91) 38 (51) 0.0036 49
Monomorphism, no. (%) 41 (55) 24 (32) 0.0309 68
Absence of tumour-infiltrating
lymphocytes, no. (%)
9 (12) 2 (3) 0.0348 97
Involvement of adnexal
epithelium, no. (%)
32 (43) 18 (24) 0.0417 76
Polypoid (exophytic)
configuration, no. (%)
0 (0) 16 (21) <0.0001 100
Prominent tumour-infiltrating
plasma cells, no. (%)
1 (1) 22 (29) <0.0001 99
Greatest diameter >10 mm,
no. (%)
2 (3) 31 (41) <0.0001 97
Ulceration, no. (%) 4 (5) 36 (48) <0.0001 95
Epidermal collarettes, no. (%) 18 (24) 53 (71) <0.0001 76
Mean mitotic rate (median, range) 4 (2, 0–23) 13 (11, 1–53) <0.0001 –
Tumour necrosis, no. (%) 2 (3) 19 (25) 0.0002 97
Multiple phenotypes, no. (%) 6 (8) 24 (32) 0.0012 92
Significant pleomorphism, no. (%) 13 (18) 31 (41) 0.0073 82
Lichenoid inflammation, no. (%) 3 (4) 14 (19) 0.0088 96
© 2017 John Wiley & Sons Ltd, Histopathology, 72, 472–480.
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number changes, including gain of 6p25, loss of
6q23, gain of 11q13, gain of 8q24, and homozygous
loss of 9p21, was recorded and considered as positive
or negative on the basis of predetermined thresh-
olds.16
Results
The final cohort consisted of 74 EDMM specimens
obtained from 44 patients, and 75 PNM specimens
obtained from 75 patients. There was no overlap of
the patient pools of the two groups. Epidermal
involvement was observed in 62 (84%) EDMM cases
and 59 (79%) PNM cases. Histopathological features
showing statistically significant differences between
EDMM and PNM by univariate analysis are listed in
Table 1. Features associated with EDMM included a
greatest dimension of <2 mm, a TIP score of 0, a
pleomorphism score of 0, a TIL score of 0, and
involvement of the adnexal epithelium (Figure 1).
Features associated with PNM included a polypoid
(exophytic) configuration, a TIP score of 2, a greatest
dimension of >10 mm, ulceration, epidermal col-
larettes, a higher mitotic rate, tumour necrosis, multi-
ple phenotypes, a pleomorphism score of 2, and
lichenoid inflammation (Figure 2). Ulceration was
seen much more frequently in lesions >10 mm (24/
33; 73%) than in lesions <10 mm (16/116; 14%)
(P < 0.0001). Other examined features did not show
significant differences between groups (Table 2). Mul-
tivariate analysis resulted in a predictive model for
PNM that included large tumour size, ulceration,
prominent TIPs, lichenoid inflammation, and epider-
mal collarettes (Table 3). The area under the ROC
Table 2. Histopathological features without statistically sig-
nificant differences between primary nodular melanoma
(PNM) and epidermotropic/dermal metastatic melanoma








Associated naevus 8 (11) 2 (3) 0.0578
Perineural invasion 12 (16) 5 (7) 0.0991
Symmetry* 12/74 (16) 20/69 (29) 0.1036
Infiltrative borders 38 (51) 52 (70) 0.1238
Lymphovascular invasion 18 (24) 10 (14) 0.1405
Regression 13 (17) 7 (9) 0.1946
Expansion of papillary
dermis by melanoma
69 (92) 54 (73) 0.2004
Pseudomaturation 15 (20) 9 (12) 0.2364
Brisk tumour-infiltrating
lymphocytes
8 (11) 5 (7) 0.4054
Tumoral melanosis 14 (19) 10 (14) 0.4379
Pseudoepitheliomatous
hyperplasia
10 (13) 7 (9) 0.4970
Architectural ‘shoulder’ 18 (24) 14 (19) 0.5017
Lentiginous growth 57 (76) 62 (84) 0.5949
Pagetoid spread 48 (64) 52 (70) 0.6455
Junctional nests 55 (73) 51 (69) 0.7559
Sheet-like growth 31 (41) 33 (45) 0.7642
Angiotropism 11 (15) 10 (14) 0.8614
Involvement of preserved
rete ridges
48 (64) 49 (66) 0.8709
*Some cases were partial biopsies in which symmetry could not be
determined.
Figure 1. Representative features associated with epidermotropic/
dermal metastatic melanoma. A, A small lesion in the upper dermis
measuring <2 mm in greatest dimension [haematoxylin and eosin
(H&E)]. B, Another lesion shows a dermal nodule with epider-
motropism, cytological monomorphism, and lack of tumour-infil-
trating lymphocytes and plasma cells (H&E).
© 2017 John Wiley & Sons Ltd, Histopathology, 72, 472–480.
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curve was 0.90, indicating a high predictive accuracy
of this model.
Six EDMM lesions from three patients were purely
or predominantly intraepidermal, and were
microscopically indistinguishable from melanoma
in situ and microinvasive melanoma (Figure 3). In
two of these patients, multiple new pigmented lesions
developed around the site of a previously resected pri-
mary scalp melanoma. Another patient presented
with multiple small pigmented lesions on the right
leg after excision of a primary right heel melanoma.
Two epidermal-only/epidermal-predominant EDMM
lesions from the two patients with scalp melanoma
were studied by FISH, which showed identical copy
number changes to those in their corresponding pri-
mary melanomas (Table S1), confirming a clonal
relationship.
Discussion
The histological distinction between cutaneous meta-
static melanoma and primary melanoma has impor-
tant diagnostic, prognostic and treatment
implications, but, to our knowledge, none of the pre-
vious studies have systematically compared the






primary nodular melanoma. A,
A large, ulcerated nodular
melanoma with an exophytic
polypoid configuration
[haematoxylin and eosin
(H&E)]. B, This tumour is
flanked by epidermal
collarettes (H&E). C, Zonal
tumour necrosis is noted in the
deeper portion of this biopsy
(H&E). D, Clusters of tumour-
infiltrating plasma cells are
present in this example (H&E).




of cells contains highly
pleomorphic and bizarre-
looking nuclei (top), whereas
the other population consists
of nests of relatively uniform
cells (bottom) (H&E).




Greatest diameter of >10 mm
(versus <2 mm)
2.2024 0.0023
Greatest diameter of 2–10 mm
(versus <2 mm)
0.5340 0.3695




Presence of lichenoid inflammation 0.7993 0.0675
Presence of epidermal collarette 0.6903 0.0028
PNM, primary nodular melanoma.
*A greater positive estimate indicates a higher probability of PNM.
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only metastatic melanoma involving the epidermis
and/or upper dermis, because these cases most closely
simulate primary melanoma. Likewise, we confined
our cohort of primary melanoma to the nodular sub-
type, as it is most likely to generate diagnostic confu-
sion with EDMM.
We identified multiple useful histopathological fea-
tures for differentiating EDMM and PNM. Of these,
tumour size is one of the most objective discriminat-
ing factors. Nodules >10 mm are more likely to
be primary, whereas lesions <2 mm are much more
likely to be metastatic. Because large melanomas
are more likely to ulcerate, we also found PNM to
be associated with ulceration. Although none of the
PNM lesions in our series was smaller than 2 mm,
one should be aware that primary ‘micromelanomas’
do exist, and may be detected more readily with the
use of dermoscopy.17,18 Hence, tumour size should
be viewed as a strong but not absolute discriminator
of metastatic and primary melanomas.
In addition to tumour size, tumour silhouette also
provides useful information. Polypoid/exophytic
lesions are much more likely to be PNM, as only one
EDMM in our series showed a polypoid silhouette.
The rarity of polypoid EDMM is also reflected in the
literature.11,19 Epidermal collarettes have been previ-
ously reported in both EDMM and primary melano-
mas.20 In our cohort, epidermal collarettes were
significantly associated with PNM. This association is
probably related to the larger tumour size in this
group, as epidermal collarettes result from expansile
dermal growth.
None of the intraepidermal features (lentiginous
growth, junctional nests, pagetoid spread, and
involvement of preserved rete ridges) are associated
with either group. Interestingly, involvement of the
adnexal epithelium is significantly associated with
EDMM, indicating that, in addition to epider-
motropism, adnexotropism is also common in meta-
static melanoma.
Although architectural shoulder was traditionally
thought to be specific for primary melanoma, later
studies have also shown this feature in EDMM.8,13,14
Our findings support the latter by showing architec-
tural shoulder in 19% of EDMMs. Notably, six EDMM
lesions from three patients were purely or predomi-
nantly intraepidermal, and were microscopically
indistinguishable from melanoma in situ and microin-
vasive melanoma. The metastatic nature of these
lesions is supported by the identical copy number
abnormalities to those in their corresponding primary
melanomas. The occurrence of multiple lesions in the
vicinity of the primary melanoma site also provides
compelling clinical evidence for metastases. However,
when clinicopathological correlation fails to elucidate
the primary versus metastatic nature of a lesion,
molecular studies may be needed to facilitate more
accurate staging.15,21
A number of cytomorphological features aid in the
distinction between PNM and EDMM. In general, sig-
nificant pleomorphism favours a diagnosis of PNM,
whereas monomorphism favours a diagnosis of
EDMM. Furthermore, primary melanomas are more
likely to comprise multiple morphologically distinct
subpopulations secondary to genetic divergence
within the tumour. In contrast, metastatic melano-
mas more commonly show one phenotype only,
A
B
Figure 3. Epidermotropic metastatic melanomas with epidermal-
predominant and epidermal-only patterns. A, This scalp lesion was
taken from near the site of a previously resected primary mela-
noma. Most of the melanoma cells are present within the epider-
mis, giving rise to an architectural ‘shoulder’ and the appearance
of a microinvasive melanoma. Adnexal involvement is also present
[haematoxylin and eosin (H&E)]. B, Another patient presented with
a purely intraepidermal metastatic melanoma on the scalp, closely
resembling melanoma in situ (H&E). [Colour figure can be viewed
at wileyonlinelibrary.com].
© 2017 John Wiley & Sons Ltd, Histopathology, 72, 472–480.
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probably reflective of a selected tumour subclone har-
bouring increased metastatic potential.22 Pseudomat-
uration, referring to partial diminution of cell size
with dermal descent, has been described in the major-
ity of naevoid melanomas23 but also in other mela-
noma subtypes, as well as EDMM. This feature is not
helpful in their distinction.
Although a coexisting naevus tends to be found
more frequently in PNM than in EDMM, the differ-
ence falls short of statistical significance
(P = 0.0578). It is well known that primary mela-
noma may arise from a pre-existing naevus via
malignant transformation. A recent study showed
that the incidence of associated naevus was highest
among superficial spreading melanomas (37%) and
lowest among nodular melanomas (16%).24 This rela-
tively low frequency in PNM may have accounted for
the lack of a significant difference from EDMM.
Although mitotic figures can be brisk in metastatic
melanoma,25 our study showed a significantly higher
mitotic rate in PNM. Nevertheless, given the wide
range and significant overlap of mitotic rates in the
two groups, the observed difference is of limited prac-
tical value. As rapidly proliferating tumours often
outgrow their blood supply, tumour necrosis may
result, and is again more commonly found in PNM.
Previous studies have found tumour necrosis to be
significantly associated with increased tumour thick-
ness, an increased Ki67 proliferation index, and
ulceration.26,27 It is therefore possible that the lower
incidence of tumour necrosis in EDMM may be, in
part, attributable to smaller tumour size and infre-
quent ulceration in this group.
Melanoma can metastasise via lymphatic,
haematogenous or angiotropic routes.28–33 Both
angiotropism and lymphovascular invasion are fair
predictors of metastatic potential in melanoma.34 In
our study, both lymphovascular invasion and angio-
tropism were seen in small subsets of PNM and
EDMM cases, and failed to distinguish between
groups. Perineural invasion is believed to be another
means by which satellite metastases form in mela-
noma. This, too, does not serve as a useful discrimi-
nator.
Our data indicate that prominent TIPs are strongly
suggestive of PNM, being observed in 29% of these
cases as compared with 1% of EDMMs. Assessment of
TIPs is fairly straightforward, making it a powerful
and practical discriminator. Mascaro et al. reported
clusters of plasma cells in 22% of primary melano-
mas, a feature that was associated with increased
Breslow thickness, ulceration, and poor survival.35 A
recent study confirmed these associations, as well as
higher mitotic activity.36 Interestingly, when found in
metastatic melanomas, TIPs were reported to consti-
tute a favourable prognosticator.37 Further investiga-
tion is needed to elucidate the immunological
relationship between TIPs and melanoma cells.
Because absence of TILs is associated with sentinel
lymph node metastasis, whereas brisk TILs are associ-
ated with prolonged recurrence-free survival,38,39 one
may expect fewer TILs in metastatic melanomas. A
study reported that a higher percentage of primary
melanomas (67%) contained lymphoid infiltrate than
metastatic foci (9%) in the same patients.40 Another
study of nodal metastatic melanomas found that TILs
were absent in 46% of cases.41 In the skin, we
showed that absence of TILs is significantly associated
with EDMM, suggesting an enhanced ability to evade
immune detection.42 Similarly, lichenoid inflamma-
tion is less common in EDMM than in PNM, despite
the essentially identical frequency of epidermal
involvement in these groups.
Perhaps contrary to common belief,11 our study
did not identify any significant difference in the fre-
quency of tumour regression. Late regression, as evi-
denced by fibrosis, increased vascularity, epidermal
atrophy, and melanophages, has been reported in
10–35% of primary melanomas.43 Although a review
article cited a much lower incidence of spontaneous
regression in metastatic melanomas (0.25%), this fig-
ure is probably skewed by the exceedingly low inci-
dence of regression in extracutaneous metastases.44
Our cohort showed regression in 17% and 9% of
PNM and EDMM cases, respectively. Several factors
may explain the lack of a significant difference. First,
regression has been reported to occur less frequently
in nodular melanoma (13%) than in other sub-
types.45 Second, the histopathological features of
regression are not specific, and may be indistinguish-
able from changes of chronic friction or prior trauma.
Finally, one of our EDMM cases with regression was
excised after immunotherapy (pembrolizumab), which
may have triggered regression of the metastatic mela-
noma.46 Tumoral melanosis—a histological variant of
regression47—similarly fails to differentiate between
PNM and EDMM.
In conclusion, we conducted the first comprehen-
sive histopathological comparison of EDMM and
PNM, and identified multiple useful discriminators
with significant associations that have not been previ-
ously reported. Of these, the collective findings of
large tumour size, ulceration, prominent TIPs, epider-
mal collarettes and lichenoid inflammation strongly
support a diagnosis of PNM on the basis of a logistic
regression model. Other highly useful characteristics
© 2017 John Wiley & Sons Ltd, Histopathology, 72, 472–480.
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based on univariate analysis include small tumour
size, and an absence of TILs, which favour EDMM,
and a polypoid configuration, tumour necrosis, and
multiple phenotypes, which favour PNM. Although
the importance of clinical correlation cannot be
overemphasised, recognition of the above constella-
tion of histopathological features, especially when the
clinical history is limited, should allow for more accu-
rate classification, and hence more precise tumour
staging and prognostication for melanoma patients.
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